OR WAIT null SECS
Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.
January 10, 2024
Clarivate's Drugs to Watch report highlights 13 potential blockbuster drugs and gamechangers set to launch in 2024.
MHRA has granted a Clinical Trial Authorization to PharmaKure for its oral combined drug for the treatment of mild cognitive impairment.
Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide.
January 03, 2024
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.
January 02, 2024
Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.